Indian generic drug maker Lupin Ltd. (500257.BY) Thursday said it has settled a patent infringement litigation with Santarus Inc. (SNTS) and DepoMed Inc. (DEPO) over the Glumetza extended-release tablets for diabetes treatment.
Lupin Settles Patent Dispute Over Glumetza Diabetes Treatment
Posted in Other News